Sanofi boosts syringe and vacc capacity at French plant

By Gareth Macdonald

- Last updated on GMT

Related tags: Sanofi-aventis, Influenza vaccine, Influenza, Sanofi

Sanofi Aventis has revamped operations at its sterile injectables plant in Le Trait, France, adding three new production units that double syringe making capacity and diversify its vaccine manufacturing capability.

The expansion is primarily designed to boost production of prefilled syringes for the low molecular-weight heparin product Lovenox, demand for which is growing at around 13 per cent a year according to the French major.

Speaking at the unveiling ceremony late last week, Sanofi CEO Christopher Viehbacher, said: “Le Trait is one of many examples of Sanofi-aventis’ desire to invest in France in order to be able to meet worldwide public health challenges​.”

Viehbacher explained that over 90 per cent of the million syringes made at the facility each day are exported, with around 25 per cent being shipped to the US.

The investment has also expanded the range of vaccine production and manufacturing operations Sanofi can undertake at the plant.

While the facility already makes the seasonal influenza vaccine Vaxigrip in collaboration with the firm’s Sanofi Pasteur unit, starting later this month will begin packaging an infant meningitis for the Japanese market.

Additionally, Sanofi will begin making its intradermal influenza vaccine Intanza early next year.

“Operator-free” containment

The €87m ($127m) expansion includes new filling, inspection and syringe packaging lines as well as innovative, “operator-free” isolation technology to prevent contamination during manufacturing operations.

The “operator-free” approach is borrowed from safety and containment principles employed in the nuclear industry which, according to Sanofi, are being applied in a number of sectors, citing French carmaker Renault as an example.

The firm also highlighted the addition of electron beam (e-beam) sterilisation technology to the product filling lines installed at the facility, which it believes will offer a way of accelerating manufacture by reducing the time its takes to decontaminate components during the process.

Related news

Show more

Related products

show more

From Candidate to Clinic- European Capabilities

From Candidate to Clinic- European Capabilities

Catalent Pharma Solutions | 22-Oct-2018 | Technical / White Paper

Catalent’s Nottingham, UK facility focuses on early stage development of small molecule drug candidates from the bench to clinic. This facility offers...

Fill Release at the Right Time in the Right Place

Fill Release at the Right Time in the Right Place

Gelita AG | 19-Sep-2018 | Technical / White Paper

From rapid release in the stomach for e.g. analgesics to enteric release for fills with unpleasant aftertaste – GELITA delivers the respective gelatine...

Accelerate your supply chain as pressures intensify

Accelerate your supply chain as pressures intensify

William Reed | 17-Sep-2018 | Technical / White Paper

Food, Drink and Non-Food manufacturers are under pressure. Range reviews, massive retail mergers, the backlash against plastic packaging and the ongoing...

Strategies to Select and Deliver the Right Candidate

Strategies to Select and Deliver the Right Candidate

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

Does your candidate have what it takes to succeed? Do you have the information needed to make the right decisions about your candidate’s path to the clinic?...

Related suppliers

Follow us

Products

View more